Pizo-A 1.5 mg Tablet

Pizo-A (Pizotifen) is a tricyclic (benzocycloheptathiophene) compound possessing structural similarities to cyproheptadine and the tricyclic antidepressants. The prophylactic effect of Pizo-A in migraine is associated with its ability to modify the humoral mechanisms of headache. It inhibits the permeability increasing effect of serotonin and histamine on the affected cranial vessels, thereby checking the transudation of plasmakinin so that the pain threshold of the receptors is maintained at 'normal' levels. In the sequence of events leading to the migraine attack, depletion of plasma serotonin contributes to loss of tone in the extracranial vessels. Pizo-A inhibits serotonin re-uptake by the platelets, thus maintaining plasma serotonin and preventing the loss of tone and passive distention of the extracranial arteries.

Pizo-A 0.5 : Each film-coated tablet contains Pizotifen Malate BP 0.725 mg equivalent to Pizotifen 0.5 mg.

Pizo-A 1.5 : Each film-coated tablet contains Pizotifen Malate BP 2.175 mg equivalent to Pizotifen 1.5 mg.

Pizo-A is indicated in the prophylactic treatment of recurrent vascular headaches, including classical migraine, common migraine and cluster headache (periodic migrainous neuralgia).

Adults

Usually 1.5 mg daily at night as a single dose or in three divided doses.

Dosage should be adjusted to individual patients requirements up to a maximum of 4.5 mg daily. Maximum single daily dose at night 3 mg

Children

Up to 1.5 mg daily , usually as a divided dose. Maximum single daily dose at night 1 mg.

OR AS DIRECTED BY THE PHYSICIAN.

The most commonly occurring side-effects are drowsiness and an increased appetite which may lead to an increase in body weight. Other side-effects such as dizziness, dry mouth, nausea, and constipation have been reported infrequently. In children, CNS stimulation may occur.

Pizo-A is contraindicated in patients hypersensitive to the drug.

Patients should be cautioned about the possibility of drowsiness and informed of its significance in the driving of vehicles and the operation of machinery. The central effects of sedatives, hypnotics, antihistamines, and alcohol may be enhanced by Pizotifen. Although its anticholinergic activity is relatively weak, Pizotifen should probably not be administered in the presence of narrow angle glaucoma or prostate hypertrophy. Dosage adjustment may be necessary in patients with kidney insufficiency. Caution is required in patients with urinary retention, narrow angle glaucoma and renal impairment.

As clinical data with Pizotifen in pregnancy are very limited, so it should only be administered during pregnancy under compelling circumstances.

Although the concentrations of Pizotifen measured in the milk of treated mothers are not likely to affect the infant, so caution should be taken in nursing mother.

Pizo-A 0.5 : Each box contains 10X10 tablets in blisters.

Pizo-A 1.5 : Each box contains 5X10 tablets in blisters.